| 臺大學術典藏 |
2020-05-26T09:27:20Z |
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
|
Soo R.A;Anderson B.O;Cho B.C;Chih-Hsin Yang;Liao M;Lim W.-T;Goldstraw P;Mok T.S.; Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG; Liao M; Lim W.-T; Goldstraw P; Mok T.S. |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
|
Soo R.A;Anderson B.O;Cho B.C;Chih-Hsin Yang;Liao M;Lim W.-T;Goldstraw P;Mok T.S.; Soo R.A; Anderson B.O; Cho B.C; CHIH-HSIN YANG; Liao M; Lim W.-T; Goldstraw P; Mok T.S. |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
|
Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:26:32Z |
Overview of current systemic management of EGFR-mutant NSCLC
|
Loong H.H.;Mok T.S;Chih-Hsin Yang;Hsu W.-H; Hsu W.-H; CHIH-HSIN YANG; Mok T.S; Loong H.H. |
| 臺大學術典藏 |
2020-05-26T09:26:32Z |
Overview of current systemic management of EGFR-mutant NSCLC
|
Loong H.H.;Mok T.S;Chih-Hsin Yang;Hsu W.-H; Hsu W.-H; CHIH-HSIN YANG; Mok T.S; Loong H.H. |
| 國立成功大學 |
2020 |
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
|
Papadimitrakopoulou, V.A.;Mok, T.S.;Han, J.-Y.;Ahn, M.-J.;Delmonte, A.;Ramalingam, S.S.;Kim, S.W.;Shepherd, F.A.;Laskin, J.;He, Y.;Akamatsu, H.;Theelen, W.S.M.E.;Su, W.-C.;John, T.;Sebastian, M.;Mann, H.;Miranda, Miranda M.;Laus, G.;Rukazenkov, Y.;Wu, Y.-L. |
| 臺大學術典藏 |
2015 |
Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
|
Mok T.S.;Smit E.F;Pen? C;Ong T.J;Schmelter T;Sun Y;Ar?n O;Juh?sz E;Novello S;Wu Y.-L;Seto T;Wakelee H.A;Chih-Hsin Yang;De Marinis F;Zhang L;Hirsh V;Paz-Ares L; Paz-Ares L; Hirsh V; Zhang L; De Marinis F; CHIH-HSIN YANG; Wakelee H.A; Seto T; Wu Y.-L; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong T.J; Penã C; Smit E.F; Mok T.S. |
| 臺大學術典藏 |
2015 |
Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
|
Mok T.S.;Smit E.F;Pen? C;Ong T.J;Schmelter T;Sun Y;Ar?n O;Juh?sz E;Novello S;Wu Y.-L;Seto T;Wakelee H.A;Chih-Hsin Yang;De Marinis F;Zhang L;Hirsh V;Paz-Ares L; Paz-Ares L; Hirsh V; Zhang L; De Marinis F; CHIH-HSIN YANG; Wakelee H.A; Seto T; Wu Y.-L; Novello S; Juhász E; Arén O; Sun Y; Schmelter T; Ong T.J; Penã C; Smit E.F; Mok T.S. |
